MiNK Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell INKT and other ETFs, options, and stocks.About INKT
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.
CEOJennifer S. Buell
CEOJennifer S. Buell
Employees23
Employees23
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2017
Founded2017
Employees23
Employees23
INKT Key Statistics
Market cap52.43M
Market cap52.43M
Price-Earnings ratio-3.68
Price-Earnings ratio-3.68
Dividend yield—
Dividend yield—
Average volume20.62K
Average volume20.62K
High today$11.52
High today$11.52
Low today$10.99
Low today$10.99
Open price$10.99
Open price$10.99
Volume6.93K
Volume6.93K
52 Week high$76.00
52 Week high$76.00
52 Week low$4.56
52 Week low$4.56
Stock Snapshot
With a market cap of 52.43M, MiNK Therapeutics(INKT) trades at $11.16. The stock has a price-to-earnings ratio of -3.68.
On 2025-11-27, MiNK Therapeutics(INKT) stock traded between a low of $10.99 and a high of $11.52. Shares are currently priced at $11.16, which is +1.6% above the low and -3.1% below the high.
MiNK Therapeutics(INKT) shares are trading with a volume of 6.93K, against a daily average of 20.62K.
During the past year, MiNK Therapeutics(INKT) stock moved between $4.56 at its lowest and $76.00 at its peak.
During the past year, MiNK Therapeutics(INKT) stock moved between $4.56 at its lowest and $76.00 at its peak.
People also own
Based on the portfolios of people who own INKT. This list is generated using Robinhood data, and it’s not a recommendation.